文献速递血液净化与透析肾血管病与高血压

血液透析房颤患者:维生素K拮抗剂与利伐沙班的多中心随机对照试验

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
PubMed 文献 · J Am Soc Nephrol · 2021-03-22

Valkyrie研究纳入132例血液透析合并房颤患者,随机接受VKA(INR 2-3)、利伐沙班10mg每日或利伐沙班联合维生素K2治疗18个月并延长随访。中位随访1.88年,利伐沙班组主要复合终点发生率显著低于VKA组(HR 0.41,95%CI 0.25-0.68,P=0.0006),利伐沙班联合维生素K2组HR 0.34(95%CI 0.19-0.61,P=0.0003),致命性和大出血风险亦显著降低。

要点

  • 血透房颤患者使用利伐沙班10mg每日较VKA显著降低主要心血管复合终点。
  • 利伐沙班较VKA显著降低致命性和大出血风险(合并HR 0.44)。
  • 利伐沙班联合维生素K2较VKA亦显著降低主要终点,出血风险有降低趋势。

核心结论

  • 在血液透析合并房颤患者中,减量利伐沙班较VKA显著降低致命性和非致命性心血管事件复合终点及大出血并发症。

研究设计与样本

  • Valkyrie研究为多中心随机对照试验,132例血液透析合并房颤患者随机分为VKA(目标INR 2-3)、利伐沙班10mg每日、利伐沙班联合维生素K2三组,治疗18个月并延长随访至少18个月。

主要发现

  • 中位随访1.88年(IQR 1.01-3.38),25%患者提前永久停用抗凝。
  • 主要终点发生率:VKA组63.8/100人年,利伐沙班组26.2/100人年,利伐沙班联合维生素K2组21.4/100人年。
  • 利伐沙班组主要终点竞争风险校正HR 0.41(95%CI 0.25-0.68,P=0.0006),联合维生素K2组HR 0.34(95%CI 0.19-0.61,P=0.0003)。
  • 全因死亡、心源性死亡和卒中风险各组无差异,但利伐沙班组症状性肢体缺血显著少于VKA组。
  • 竞争风险校正后,利伐沙班组致命性和大出血HR 0.39(95%CI 0.17-0.90,P=0.03),联合维生素K2组HR 0.48(95%CI 0.22-1.08,P=0.08),利伐沙班合并组HR 0.44(95%CI 0.23-0.85,P=0.02)。

临床怎么用

  • 血液透析合并房颤患者可考虑使用减量利伐沙班(10mg每日)替代VKA抗凝,以降低心血管事件和出血风险。

局限性

  • 原文未报告样本量计算、盲法设计及开放标签等具体方法学局限,仅提及25%患者提前永久停用抗凝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with normal renal function or early stage CKD, the risk-benefit profile of direct oral anticoagulants (DOACs) is superior to that of vitamin K antagonists (VKAs). In patients on hemodialysis, the comparative efficacy and safety of DOACs versus VKAs are unknown. METHODS: In the Valkyrie study, 132 patients on hemodialysis with atrial fibrillation were randomized to a VKA with a target INR of 2-3, 10 mg rivaroxaban daily, or rivaroxaban and vitamin K2 for 18 months. Patients continued the originally assigned treatment and follow-up was extended for at least an additional 18 months. The primary efficacy end point was a composite of fatal and nonfatal cardiovascular events. Secondary efficacy end points were individual components of the composite outcome and all-cause death. Safety end points were life-threatening, major, and minor bleeding. RESULTS: Median (IQR) follow-up was 1.88 (1.01-3.38) years. Premature, permanent discontinuation of anticoagulation occurred in 25% of patients. The primary end point occurred at a rate of 63.8 per 100 person-years in the VKA group, 26.2 per 100 person-years in the rivaroxaban group, and 21.4 per 100 person-years in the rivaroxaban and vitamin K2 group. The estimated competing risk-adjusted hazard ratio for the primary end point was 0.41 (95% CI, 0.25 to 0.68; P=0.0006) in the rivaroxaban group and 0.34 (95% CI, 0.19 to 0.61; P=0.0003) in the rivaroxaban and vitamin K2 group, compared with the VKA group. Death from any cause, cardiac death, and risk of stroke were not different between the treatment arms, but symptomatic limb ischemia occurred significantly less frequently with rivaroxaban than with VKA. After adjustment for competing risk of death, the hazard ratio for life-threatening and major bleeding compared with the VKA group was 0.39 (95% CI, 0.17 to 0.90; P=0.03) in the rivaroxaban group, 0.48 (95% CI, 0.22 to 1.08; P=0.08) in the rivaroxaban and vitamin K2 group and 0.44 (95% CI, 0.23 to 0.85; P=0.02) in the pooled rivaroxaban groups. CONCLUSIONS: In patients on hemodialysis with atrial fibrillation, a reduced dose of rivaroxaban significantly decreased the composite outcome of fatal and nonfatal cardiovascular events and major bleeding complications compared with VKA. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Oral Anticoagulation in Hemodialysis, NCT03799822.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol. 2021. PMID: 33753537. doi:10.1681/ASN.2020111566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。